PNPLA3 and metabolic dysfunction-associated steatohepatitis: These eight bioactive components of AGE expressed binding affinity for PNPLA3, suggesting that AGE as a compound may target PNPLA3 as a core protein to reduce the NASH progression as shown (Figure 22).